Ji Han Bi, Kim Cho Rim, Min Chang Hee, Han Jae Hoon, Kim Se-Na, Lee Cheol, Choy Young Bin
Interdisciplinary Program in Bioengineering College of Engineering, Seoul National University Seoul Republic of Korea.
Institute of Medical & Biological Engineering, Medical Research Center, Seoul National University Seoul Republic of Korea.
Bioeng Transl Med. 2023 Feb 1;8(3):e10477. doi: 10.1002/btm2.10477. eCollection 2023 May.
Chemodynamic therapy (CDT) is based on the production of cytotoxic reactive oxygen species, such as hydroxyl radicals (OH). Thus, CDT can be advantageous when it is cancer-specific, in terms of efficacy and safety. Therefore, we propose NH-MIL-101(Fe), a Fe-containing metal-organic framework (MOF), as a carrier of Cu (copper)-chelating agent, d-penicillamine (d-pen; i.e., the NH-MIL-101(Fe)/d-pen), as well as a catalyst with Fe-metal clusters for Fenton reaction. NH-MIL-101(Fe)/d-pen in the form of nanoparticles was efficiently taken into cancer cells and released d-pen in a sustained manner. The released d-pen chelated Cu that is highly expressed in cancer environments and this produces extra HO, which is then decomposed by Fe in NH-MIL-101(Fe) to generate OH. Therefore, the cytotoxicity of NH-MIL-101(Fe)/d-pen was observed in cancer cells, not in normal cells. We also suggest a formulation of NH-MIL-101(Fe)/d-pen combined with NH-MIL-101(Fe) loaded with the chemotherapeutic drug, irinotecan (CPT-11; NH-MIL-101(Fe)/CPT-11). When intratumorally injected into tumor-bearing mice in vivo, this combined formulation exhibited the most prominent anticancer effects among all tested formulations, owing to the synergistic effect of CDT and chemotherapy.
化学动力疗法(CDT)基于细胞毒性活性氧的产生,例如羟基自由基(OH)。因此,就疗效和安全性而言,当CDT具有癌症特异性时可能具有优势。因此,我们提出将含Fe的金属有机框架(MOF)NH-MIL-101(Fe)作为铜(Cu)螯合剂d-青霉胺(d-pen;即NH-MIL-101(Fe)/d-pen)的载体,以及用于芬顿反应的具有Fe金属簇的催化剂。纳米颗粒形式的NH-MIL-101(Fe)/d-pen能有效地进入癌细胞并持续释放d-pen。释放出的d-pen螯合在癌症环境中高表达的Cu,这会产生额外的H₂O₂,然后其被NH-MIL-101(Fe)中的Fe分解以生成OH。因此,在癌细胞而非正常细胞中观察到了NH-MIL-101(Fe)/d-pen的细胞毒性。我们还提出了一种NH-MIL-101(Fe)/d-pen与负载化疗药物伊立替康(CPT-11;NH-MIL-101(Fe)/CPT-11)的NH-MIL-101(Fe)联合的制剂。当在体内瘤内注射到荷瘤小鼠体内时,由于CDT和化疗的协同作用,这种联合制剂在所有测试制剂中表现出最显著的抗癌效果。